Clinical Trial Update: Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating citalopram as a posterior cortical protective therapy in Parkinson disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Citalopram (Citalopram hydrobromide)

Snippet

Sponsor: University of Michigan | Conditions: Parkinson Disease | Phase 2 | Status: COMPLETED